Heidelberg Pharma AG will receive gross issue proceeds of EUR 34,427,274 million from the corporate action, which will be used to finance the Company’s ATAC development programs.
Ladenburg, Germany, 21 November 2017 - Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today successfully completed the capital measure adopted on 3 November 2017 and generated gross issue proceeds of approximately EUR 34.4 million (including the contribution in kind) by placing the maximum allowable number of new shares and issuing convertible bonds. A total of 7,484,190 new shares at a price of EUR 2.60 each and 14,968,380 convertible bonds with a principal amount of EUR 1.00 each were placed with existing shareholders of Heidelberg Pharma AG and new, institutional investors. The capital measure was oversubcribed.
Heidelberg Pharma AG will receive gross issue proceeds of EUR 34,427,274 million (including the contribution in kind) from the corporate action, which will be used to finance the Company’s ATAC development programs.
As part of the capital measure, the Company’s main shareholder, dievini Hopp BioTech Holding & Co. KG, Walldorf, Germany, (dievini) acquired 1,511,128 new shares in return for contributing a repayment claim under the loan agreement dated 11 October 2016, 4,241,834 new shares in exchange for a cash contribution, and 13,882,276 convertible bonds.
Dr Jan Schmidt-Brand, CEO and CFO of Heidelberg Pharma AG, commented: “We are pleased to have completed this capital measure successfully and would like to thank our shareholders for their trust and support. Through this extensive capital measure, we have secured the funds required in particular to launch the clinical development of our development candidate HDP-101, and we expect these funds to be sufficient to continue development until initial indications of efficacy in patients are available. Extending the financing reach of Heidelberg Pharma AG to 2020 enables us to fully focus on the further development of our HDP-101 project and its underlying technologies.”
Once the execution of the capital increase has been recorded in the Commercial Register at Mannheim Local Court, the new share capital of the Company will be EUR 22,452,570.00 divided into 22,452,570 no par value bearer shares. The gross issue
proceeds from the new shares amount to EUR 19,458,894, thereof EUR 15,529,961 from the cash contribution and EUR 3,928,933 from the contribution in kind. Heidelberg Pharma has thus fully utilized the authorized capital available for the issuance of new shares.
Heidelberg Pharma has generated gross issue proceeds of EUR 14,968,380 from issuing 14,968,380 convertible bonds with a principal amount of EUR 1.00 each. The Company will not make any interest payments on the convertible bonds (zero-coupon bonds). The bond creditors have the right to convert the convertible bonds into a maximum of 5,757,069 new shares at a conversion price of EUR 2.60 per share from 11 January 2018 up to the final maturity date, subject to certain lock-up periods. At the end of the two-year term starting on the issue date, the Company may request that the convertible bonds be converted into shares of the Company.
Baader Bank AG, Unterschleissheim, Germany, managed the capital measure as global coordinator and sole bookrunner.
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
| Contact Heidelberg Pharma AG Sylvia Wimmer Tel.: +49 89 41 31 38-29 Email: investors[at]hdpharma.com Schriesheimer Str. 101, 68526 Ladenburg | IR/PR support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89 210 228-40 |
